Sanofi makes fifth M&A deal this year, with Origimm acquisition

Acquisition hungry Sanofi (Euronext: SAN) has announced the fifth such deal for this year, revealing that it has reached agreement to buy Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne.

With this acquisition, the French pharma major says it continues executing its global Play to Win strategy, pursuing growth opportunities and building an industry-leading vaccines pipeline.

The transaction will add ORI-001 to Sanofi’s early-stage pipeline. ORI-001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in third-quarter 2021.